03 Oct 2026, 15:02 IST
Lupin Limited
Motilal Oswal (MOFSL) · Neutral
The report notes Lupin's US sales are expected to dip 18% sequentially due to competition in Mirabegron and Tolvaptan, with an 11% YoY EBITDA decline.
From HEALTHCARE MOFSL PR PG024, written by Motilal Oswal (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.